Treatment Equity in the Immunotherapy Era: Options for Patients with Both Autoimmune Disease and GU Cancers

Numerous immunotherapeutic agents, such as immune checkpoint inhibitors (ICIs), have been approved for the treatment of genitourinary (GU) malignancies. While ICIs have improved treatment outcomes and expanded treatment options, they can cause immune-related adverse events (irAEs). The scope of irAE...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Gavin, Drolen, Claire, Hannigan, Christopher A., Drakaki, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949122/
https://www.ncbi.nlm.nih.gov/pubmed/35330111
http://dx.doi.org/10.3390/life12030360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949122/
https://www.ncbi.nlm.nih.gov/pubmed/35330111
http://dx.doi.org/10.3390/life12030360

Ejemplares similares